Agile Sciences, Inc. is an emerging biopharmaceutical company that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections.

Agile Sciences’ core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action resulting in enhanced antibiotic activity.

Our 2-AI compounds have been shown to:

Restore the activity of antibiotics against multidrug-resistant Gram-positive and Gram-negative bacterial pathogens

 Inhibit and disperse bacterial communities, known as biofilms

 Mitigate the acquisition of antibiotic resistance

 Display a novel mode of action through inhibiting the response regulator protein of bacterial two-component systems

Agile Sciences is exploiting the above attributes of the 2-AI compounds in three therapeutic areas that are difficult-to-treat:

1) Multidrug-resistant bacterial infections

2) Lung infections in cystic fibrosis patients

3) Chronic wound infections